What should hospitals prioritize when buying implants for the Avascular Necrosis Market?

Long-term registry survivorship should outweigh list price. Cementless systems with ten-year revision rates below 5% in national registries reduce costly revisions in younger patients [7]. Read More

How do reimbursement codes differ for joint-preserving procedures?

Core decompression has its own CPT code, but bone marrow concentrate harvesting is often bundled or denied. Providers should verify payer policies before scheduling cell-augmented cases [9]. Read More

Which emerging use case could change the Avascular Necrosis Market most?

Opportunistic AI screening of routine pelvic MRI and CT scans ordered for other reasons. It could flag silent, pre-collapse lesions in steroid-treated patients before symptoms appear [11]. Read More

Is jaw osteonecrosis included in the Avascular Necrosis Market scope?

No. Medication-related osteonecrosis of the jaw has different causes, specialists and products, so it is excluded from these estimates [10]. Read More

What integration challenge slows AI adoption in orthopedic imaging?

Most algorithms are trained on single-center data and lose accuracy on scanners from other vendors. Hospitals need local validation and PACS integration before relying on automated staging [11]. Read More

How attractive is the Avascular Necrosis Market for new entrants?

Device entry is difficult because registry history and robotic ecosystems lock in surgeons. Biologics and diagnostic software offer lower-barrier entry points with faster regulatory routes [12]. Read More

Do generic drug suppliers face regulatory hurdles in this field?

No avascular necrosis-specific drug has regulatory approval, so suppliers market products under existing labels. Promotion for off-label use remains restricted in the U.S. and EU [21]. Read More

Avascular Necrosis Market (2026 - 2035)

ID: MRFR/MED/4673-CR 539 Pages Rahul Gotadki Last Updated: November 03, 2026

Avascular Necrosis Market Research Report Information By Type (Trauma Related Avascular Necrosis (AVN) and Non-Trauma Related Avascular Necrosis (AVN)0, By Treatment (Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Cholesterol Lowing Drugs, Osteoporosis Drugs, Blood Thinners, and Others), By Diagnosis (Imaging, Biopsy, CT Scan, PET and X- Ray), By End User (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Avascular Necrosis Market

Market Size

Forecast Period2026-2035

CAGR (2026-2035)6.6%

2025 Market SizeUSD 689.3 Million

2035 Market SizeUSD 1,334.4 Million

Key Players

Stryker

Zimmer Biomet

Johnson & Johnson MedTech

Smith+Nephew

Enovis

Medtronic

Trends

Rising Corticosteroid and Alcohol Exposure
Ageing Populations and Growing THA Volumes
MRI and AI-Assisted Early Detection

Opportunities

Public Insurance Expansion in India and Southeast Asia
Imaging Data Platforms and Subscription Analytics
Outpatient Hip Reconstruction Pathways

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Summary | |
2 Key Report Takeaways | |
1. 2.1 By Treatment Type | |
2. 2.2 By Disease Type | |
3. 2.3 By Diagnosis | |
4. 2.4 By End User | |
5. 2.5 By Region | |
3 Market Size and Forecast (2021–2035) | |
4 Driver Impact Analysis | |
1. 4.1 Rising Corticosteroid and Alcohol Exposure | |
2. 4.2 Ageing Populations and Growing THA Volumes | |
3. 4.3 MRI and AI-Assisted Early Detection | |
4. 4.4 Robotic and Cementless Implant Innovation | |
5. 4.5 Cell-Augmented Joint-Preserving Procedures | |
6. 4.6 Sickle Cell Disease Burden and Screening Programs | |
5 Restraints Impact Analysis | |
1. 5.1 Volume-Based Procurement Price Cuts | |
2. 5.2 Late Diagnosis and Limited MRI Access | |
3. 5.3 Weak Evidence for Pharmacologic Therapy | |
4. 5.4 EU MDR Compliance Costs | |
5. 5.5 Implant Recalls and Product Liability | |
6 Opportunities | |
1. 6.1 Public Insurance Expansion in India and Southeast Asia | |
2. 6.2 Imaging Data Platforms and Subscription Analytics | |
3. 6.3 Outpatient Hip Reconstruction Pathways | |
4. 6.4 Orthobiologics for Pre-Collapse Disease | |
5. 6.5 Sickle Cell Care Networks in Africa and the Middle East | |
7 Regional Market Share and Country-Level Analysis | |
1. 7.1 North America | | |
  1. 7.1.1 United States | | |
  2. 7.1.2 Canada | | |
  3. 7.1.3 Mexico | |
2. 7.2 Europe | | |
  1. 7.2.1 Germany | | |
  2. 7.2.2 United Kingdom | | |
  3. 7.2.3 France | | |
  4. 7.2.4 Italy | | |
  5. 7.2.5 Spain | | |
  6. 7.2.6 Nordic Countries | | |
  7. 7.2.7 Russia | | |
  8. 7.2.8 Rest of Europe | |
3. 7.3 Asia-Pacific | | |
  1. 7.3.1 China | | |
  2. 7.3.2 India | | |
  3. 7.3.3 Japan | | |
  4. 7.3.4 South Korea | | |
  5. 7.3.5 ASEAN | | |
  6. 7.3.6 Rest of Asia-Pacific | |
4. 7.4 South America | | |
  1. 7.4.1 Brazil | | |
  2. 7.4.2 Argentina | | |
  3. 7.4.3 Rest of South America | |
5. 7.5 Middle East & Africa | | |
  1. 7.5.1 Saudi Arabia | | |
  2. 7.5.2 UAE | | |
  3. 7.5.3 South Africa | | |
  4. 7.5.4 Egypt | | |
  5. 7.5.5 Rest of Middle East & Africa | |
8 Future Outlook (2026–2035) | |
1. 8.1 AI-Guided Staging and Triage | |
2. 8.2 Robotic Surgery and the Outpatient Shift | |
3. 8.3 Regenerative Therapy Pipeline | |
4. 8.4 Value-Based Payment and Registry Accountability | |
9 Segmentation Analysis | |
1. 9.1 By Treatment Type | | |
  1. 9.1.1 Drugs | | | |
    1. 9.1.1.1 Nonsteroidal Anti-Inflammatory Drugs | | | |
    2. 9.1.1.2 Cholesterol-Lowering Drugs | | | |
    3. 9.1.1.3 Blood Thinners | | | |
    4. 9.1.1.4 Other Drugs | | |
  2. 9.1.2 Bone Replacement Devices & Implants | | | |
    1. 9.1.2.1 Bone Grafts | | | |
    2. 9.1.2.2 Joint Replacement Surgery | | | |
    3. 9.1.2.3 Cementless Prosthesis | |
2. 9.2 By Disease Type | | |
  1. 9.2.1 Traumatic Avascular Necrosis | | |
  2. 9.2.2 Non-Traumatic Avascular Necrosis | | |
  3. 9.2.3 Fracture-Induced | | |
  4. 9.2.4 Dislocation-Induced | | |
  5. 9.2.5 Post-Surgical | | |
  6. 9.2.6 Crush Injury-Related | | |
  7. 9.2.7 Sports Injury-Associated | | |
  8. 9.2.8 Steroid-Induced | | |
  9. 9.2.9 Alcohol-Induced | | |
  10. 9.2.10 Sickle Cell Disease-Associated | | |
  11. 9.2.11 Lupus-Related | | |
  12. 9.2.12 Radiation Therapy-Induced | | |
  13. 9.2.13 Idiopathic | |
3. 9.3 By Diagnosis | | |
  1. 9.3.1 Imaging | | |
  2. 9.3.2 Biopsy | | |
  3. 9.3.3 Computed Tomography Scan | | |
  4. 9.3.4 Positron Emission Tomography | | |
  5. 9.3.5 X-Ray | | |
  6. 9.3.6 Others | |
4. 9.4 By End User | | |
  1. 9.4.1 Hospitals | | |
  2. 9.4.2 Specialty Clinics | | |
  3. 9.4.3 Ambulatory Surgical Centers | | |
  4. 9.4.4 Rehabilitation Centers | | |
  5. 9.4.5 Home Care Settings | | |
  6. 9.4.4 Others | |
10 Competitive Landscape | |
1. 10.1 Market Concentration Analysis | |
2. 10.2 Competitive Benchmarking Matrix | |
11 Recent News & Developments | |
12 Report Scope and Methodology | |
13 Detailed Sources and Citations | |
14 Frequently Asked Questions (FAQs) | | LIST OF TABLES | |
TABLE 1 Global Avascular Necrosis Market Summary, 2025–2035 | |
TABLE 2 Global Avascular Necrosis Market Size & Forecast, by Revenue (USD Million), 2021–2035 | |
TABLE 3 Driver Impact Analysis | |
TABLE 4 Restraints Impact Analysis | |
TABLE 5 Global Avascular Necrosis Market, by Region, 2025 | |
TABLE 6 North America Avascular Necrosis Market, by Country, 2025 | |
TABLE 7 Europe Avascular Necrosis Market, by Country, 2025 | |
TABLE 8 Asia-Pacific Avascular Necrosis Market, by Country, 2025 | |
TABLE 9 South America Avascular Necrosis Market, by Country, 2025 | |
TABLE 10 Middle East & Africa Avascular Necrosis Market, by Country, 2025 | |
TABLE 11 Global Avascular Necrosis Market, by Treatment Type, 2025 | |
TABLE 12 Global Avascular Necrosis Market, by Disease Type, 2025 | |
TABLE 13 Global Avascular Necrosis Market, by Diagnosis, 2025 | |
TABLE 14 Global Avascular Necrosis Market, by End User, 2025 | |
TABLE 15 Competitive Benchmarking Matrix – Global Avascular Necrosis Market | |
TABLE 16 Report Scope and Methodology | |
TABLE 17 Detailed Sources and Citations | | LIST OF FIGURES | |
FIGURE 1 Market Dynamics Overview – Drivers, Restraints and Opportunities | |
FIGURE 2 Avascular Necrosis Value Chain Analysis | |
FIGURE 3 Porter's Five Forces Analysis | |
FIGURE 4 Global Avascular Necrosis Market Size Trend, 2021–2035 (USD Million) | |
FIGURE 5 Market Share by Treatment Type, 2025 | |
FIGURE 6 Market Share by Disease Type, 2025 | |
FIGURE 7 Market Share by Diagnosis, 2025 | |
FIGURE 8 Market Share by End User, 2025 | |
FIGURE 9 Regional Market Share, 2025 | |
FIGURE 10 Competitive Landscape – Estimated Revenue Share Ranges of Key Players

Certified Researchers

Enquiry

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Treatment Type	Drugs; Bone Replacement Devices & Implants	Bone Replacement Devices & Implants (57.6% share)	Total Hip Implants (7.8% CAGR)
By Disease Type	Traumatic Avascular Necrosis; Non-Traumatic Avascular Necrosis	Non-Traumatic Avascular Necrosis (64.0% share)	Steroid-Induced (7.3% CAGR)
By Diagnosis	Imaging; Biopsy; Others	Imaging (50.4% share)	MRI (8.2% CAGR)
By End User	Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Others	Hospitals (58.3% share)	Ambulatory Surgical Centers (7.9% CAGR (2026–2035))
By Region	North America; Europe; Asia-Pacific; South America; Middle East & Africa	North America (39.6% share)	Asia-Pacific (8.3% CAGR (2026–2035))

Market Segmentation Overview

By Treatment Type

Sub-Segment	Key Trend
Drugs	Statins, anticoagulants and bisphosphonates used in pre-collapse care; biologic combinations under study
Bone Replacement Devices & Implants	Cementless total hip implants and robotic placement gaining share

Bone Replacement Devices & Implants lead treatment revenue because most patients reach surgeons after collapse, leaving total hip arthroplasty as the definitive option. Within the segment, total hip implants grow fastest as cementless fixation and robotic placement suit younger patients. Drugs hold a steady supporting role in early disease, but weak trial evidence keeps their growth below that of implants.

By Disease Type

Sub-Segment	Key Trend
Traumatic Avascular Necrosis	Early fracture fixation and hip-preserving surgery
Non-Traumatic Avascular Necrosis	Rising steroid-induced and multifocal presentations

Non-Traumatic Avascular Necrosis leads because corticosteroid and alcohol exposure produce bilateral, multifocal disease that multiplies imaging and surgery per patient. Its steroid-induced sub-segment grows fastest, reinforced by the post-COVID-19 cohort. Traumatic Avascular Necrosis remains a large secondary pool where early detection after fracture favors preservation procedures.

By Diagnosis

Sub-Segment	Key Trend
Imaging	MRI-led staging with AI-assisted interpretation
Biopsy	Declining use as image resolution improves
Others	Bone scintigraphy retained for multifocal workups

Imaging leads diagnosis and MRI is its fastest-growing modality, because marrow edema is visible on MRI well before radiographic change and AI tools now support non-specialist readers. Biopsy is shrinking toward a confirmatory role for indeterminate lesions, while other methods such as bone scintigraphy persist mainly in multifocal disease.

By End User

Sub-Segment	Key Trend
Hospitals	Integrated imaging, surgery and multidisciplinary care
Specialty Clinics	Long-term monitoring and drug management
Ambulatory Surgical Centers	Outpatient total hip arthroplasty growth
Others	Research-led regenerative therapy trials

Hospitals lead because complex bilateral cases need MRI, operating capacity and multidisciplinary teams under one roof. Ambulatory Surgical Centers grow fastest as payers shift healthy THA patients to outpatient settings. Specialty Clinics retain a monitoring role for pre-collapse patients on drug therapy.

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”